Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29053128 | 1.00 | NPSR1 (0.50) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL1195036 | 1.00 | NPSR1 (0.50) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10496345 | 0.88 | NPSR1 (0.47) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10496348 | 0.88 | NPSR1 (0.47) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL5153122 | 0.85 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL2955503 | 0.85 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL8960689 | 0.85 | NPSR1 (0.52) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL29991192 | 0.83 | NPSR1 (0.50) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL18290046 | 0.83 | NPSR1 (0.54) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL15482738 | 0.82 | NPSR1 (0.48) | NPSR1HCAR2ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279744-B | Method for the conversion of biologically derived mevalonate | 维索利斯有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-107002104-B | Method for conversion of biologically derived mevalonate | 维索利斯有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-112279744-A | Method for conversion of biologically derived mevalonate | 维索利斯有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-107002104-A | Method for conversion of biologically derived mevalonate | 维索利斯有限公司 | 2017-08-01 | — | — | CN | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884128-B2 | reacting 11-{[tert-butyl(dimethyl)silyl]oxy}-7-[(E)-2-formyl-1-methyleth-1-en-1-yl]-6,13a-dimethyl-2-phenyl-3a,6,7,10,11,12,13,13a-octahydro-9H-[1,3]dioxolo[4,5-f]oxacyclododecin-9-one with 2-methyl-3-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]propyl}oxiran-2-yl)pentane-3-ol, to form pladienolide analogues | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | KANADA REGINA MIKIE | 2010-08-12 | — | — | US | disclosed |
| CN-101663296-A | 12-membered ring macrolactam derivatives | EISAI R&D MAN CO LTD | 2010-03-03 | — | — | CN | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1935893-A1 | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | Eisai R&D Management Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935893-A1 | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | Eisai R&D Management Co., Ltd. (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | EISAI R&D MANAGEMENT CO., LTD. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, HDAC1, HDAC3 | NPSR1 3510/4885HCAR2 2143/4885ALDH1A1 2190/4885 |
| US-20100204490-A1 | PROCESS FOR TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D | CYP8B1, PLA2G2D, HPD | NPSR1 1887/4885HCAR2 921/4885ALDH1A1 2637/4885 |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC1 | NPSR1 3386/4885HCAR2 2202/4885ALDH1A1 2310/4885 |
| US-20080021226-A1 | Process for total synthesis of pladienolide B and pladienolide D | TPD52L2, CYP8B1, HPD | NPSR1 2254/4885HCAR2 1567/4885ALDH1A1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.